Cell Therapy News Volume 24.18 | May 29 2023

May 29, 2023

2023-05-29 | CTN 24.18

Cell Therapy News by STEMCELL Technologies

Vol. 24.18 – 29 May, 2023

TOP STORY

Tumor-Intrinsic Sensitivity to the Pro-Apoptotic Effects of IFN-γ Is a Major Determinant of CD4⁺ CAR T-Cell Antitumor Activity

With the help of functional intravital imaging, scientists reported that interferon (IFN)-γ production but not perforin-mediated cytotoxicity was the dominant mechanism for tumor elimination by anti-CD19 CD4⁺ CAR T cells.
[Nature Cancer]

Full Article

Return to your lab safely and efficiently with these guides and resources so that you can focus more on moving your research goals forward.

PUBLICATIONSRanked by the impact factor of the journal

Hematopoietic Reconstitution Dynamics of Mobilized- and Bone Marrow-Derived Human Hematopoietic Stem Cells After Gene Therapy

Investigators presented an exploratory analysis evaluating the hematopoietic reconstitution kinetics, engraftment, and clonality in 13 pediatric Wiskott-Aldrich syndrome patients.
[Nature Communications]

Full Article

Rescue of Auditory Function by a Single Administration of AAV-TMPRSS3 Gene Therapy in Aged Mice of Human Recessive Deafness DFNB8

A single adeno-associated virus-humanTMPRSS3 injection in Tmprss^3A306T/A306T mice of an average age of 18.5 months led to the sustained rescue of the auditory function to a level similar to wild-type mice.
[Molecular Therapy]

Full Article Graphical Abstract

Suicide Gene Therapy Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cell Gene Delivery Vehicles in Recurrent Glioblastoma Multiforme: A First-in-Human, Dose-Escalation, Phase I Clinical Trial

Researchers showed that suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cells carrying the herpes simplex virus-thymidine kinase gene was safe in patients with recurrent glioblastoma multiforme.
[Journal Of Translational Medicine]

Full Article

Transplantation of Human Brain-Derived Ischemia-Induced Multipotent Stem Cells Ameliorates Neurological Dysfunction in Mice After Stroke

Investigators performed a preclinical study by transplanting human brain-derived-induced multipotent stem cells transcranially into post-stroke mouse brains six weeks after middle cerebral artery occlusion.
[Stem Cells Translational Medicine]

Full Article
Graphical
Abstract

Lenalidomide Overcomes the Resistance to Third-Generation CD19-CAR-T Cell Therapy in Preclinical Models of Diffuse Large B-Cell Lymphoma

Germinal center B-cell-like diffuse large B-cell lymphoma cell line OCI-Ly1, and patient-derived xenografted mice were used as the CAR-T cell-resistant model.
[Cellular Oncology]

Abstract

A Novel Bispecific T-Cell Engager (BiTE) Targeting CD22 and CD3 Has Both In Vitro and In Vivo Activity and Synergizes With Blinatumomab in an Acute Lymphoblastic Leukemia (ALL) Tumor Model

Scientists reported the development of a new BiTE with cytotoxic activity against CD22⁺ cells which could represent an alternate or complementary therapeutic option for B cell malignancies.
[Cancer Immunology Immunotherapy]

Full Article

VEGF Overexpressed Mesoangioblasts Enhance Urethral and Vaginal Recovery Following Simulated Vaginal Birth in Rats

Female rats were assigned to either injection of saline, allogeneic-mesoangioblasts (MABs), autologous-MABs, or allogeneic-MABs transduced to stably expressed vascular endothelial growth factor (VEGF).
[Scientific Reports]

Full Article

Infectious Complications Following CAR-T Cell Therapy for B Cell Non-Hodgkin Lymphoma: A Single-Center Experience and Review of the Literature

Investigators reported a single-center retrospective study of infectious complications following CAR-T cell therapy in 48 adult patients with relapsed and refractory B cell non-Hodgkin lymphoma.
[Annals Of Hematology]

Full Article

Virtual Conference Exhibition: Pluripotent Stem Cells

REVIEWS

Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplants

The authors review the most recent management strategies for Cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
[International Journal Of Antimicrobial Agents]

Abstract

INDUSTRY AND POLICY NEWS

Iovance Biotherapeutics Announces US Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Iovance Biotherapeutics, Inc. announced that the US FDA accepted its Biologics License Application for Lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.
[Iovance Biotherapeutics, Inc.]

Press Release

FEATURED EVENT

Cell Therapy News Volume 24.18 | May 29 2023

Tumor-Intrinsic Sensitivity to the Pro-Apoptotic Effects of IFN-γ Is a Major Determinant of CD4⁺ CAR T-Cell Antitumor Activity

Hematopoietic Reconstitution Dynamics of Mobilized- and Bone Marrow-Derived Human Hematopoietic Stem Cells After Gene Therapy

Rescue of Auditory Function by a Single Administration of AAV-TMPRSS3 Gene Therapy in Aged Mice of Human Recessive Deafness DFNB8

Suicide Gene Therapy Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cell Gene Delivery Vehicles in Recurrent Glioblastoma Multiforme: A First-in-Human, Dose-Escalation, Phase I Clinical Trial

Transplantation of Human Brain-Derived Ischemia-Induced Multipotent Stem Cells Ameliorates Neurological Dysfunction in Mice After Stroke

Lenalidomide Overcomes the Resistance to Third-Generation CD19-CAR-T Cell Therapy in Preclinical Models of Diffuse Large B-Cell Lymphoma

A Novel Bispecific T-Cell Engager (BiTE) Targeting CD22 and CD3 Has Both In Vitro and In Vivo Activity and Synergizes With Blinatumomab in an Acute Lymphoblastic Leukemia (ALL) Tumor Model

VEGF Overexpressed Mesoangioblasts Enhance Urethral and Vaginal Recovery Following Simulated Vaginal Birth in Rats

Infectious Complications Following CAR-T Cell Therapy for B Cell Non-Hodgkin Lymphoma: A Single-Center Experience and Review of the Literature

Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplants

Iovance Biotherapeutics Announces US Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Annual Regenerative Medicine Essentials Summer Course and RMF Stem Cell Summit

> See All Events

Research Associate – Cancer Research

Technical Associate – iPSCs, CRISPR

Postdoctoral Scientist – Immunotherapy

Postdoctoral Fellow – Tumor Microenvironment

Postdoctoral Fellow – Stem Cell and Regenerative Medicine

> See All Jobs